-
Something wrong with this record ?
Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients
S. Merdita, P. Ryšánek, J. M. Hartinger, O. Slanař, M. Šíma
Language English Country Czech Republic
Document type Journal Article, Review
Grant support
VFN00064165
Ministerstvo Zdravotnictví Ceské Republiky
NLK
Directory of Open Access Journals
from 2012
Medline Complete (EBSCOhost)
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- MeSH
- Immunosuppressive Agents * pharmacokinetics administration & dosage MeSH
- Precision Medicine MeSH
- Mycophenolic Acid * pharmacokinetics administration & dosage MeSH
- Humans MeSH
- Graft Rejection prevention & control MeSH
- Organ Transplantation * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Mycophenolate mofetil (MMF) is an immunosuppressant drug approved for prophylaxis of transplant rejection in patients undergoing solid organ transplantation and is further employed in management of various autoimmune disorders. MMF exhibits notable pharmacokinetic inter- and intraindividual variability necessitating tailored therapeutic approaches to achieve optimal therapeutic outcomes while mitigating risks of adverse effects. The objective of this review was to summarize factors that influence the pharmacokinetics of MMF and its active metabolite mycophenolic acid in order to deduce recommendations for personalized treatment strategies. Presumed predictors were analysed in relation to each of the four pharmacokinetic phases, providing tools and targets for MMF dosing optimization amenable to clinical implementation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017619
- 003
- CZ-PrNML
- 005
- 20250513151731.0
- 007
- ta
- 008
- 241004s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.14712/23362936.2024.18 $2 doi
- 035 __
- $a (PubMed)39171547
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Merdita, Sara, $d 1999- $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0331992
- 245 10
- $a Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients / $c S. Merdita, P. Ryšánek, J. M. Hartinger, O. Slanař, M. Šíma
- 520 9_
- $a Mycophenolate mofetil (MMF) is an immunosuppressant drug approved for prophylaxis of transplant rejection in patients undergoing solid organ transplantation and is further employed in management of various autoimmune disorders. MMF exhibits notable pharmacokinetic inter- and intraindividual variability necessitating tailored therapeutic approaches to achieve optimal therapeutic outcomes while mitigating risks of adverse effects. The objective of this review was to summarize factors that influence the pharmacokinetics of MMF and its active metabolite mycophenolic acid in order to deduce recommendations for personalized treatment strategies. Presumed predictors were analysed in relation to each of the four pharmacokinetic phases, providing tools and targets for MMF dosing optimization amenable to clinical implementation.
- 650 12
- $a kyselina mykofenolová $x farmakokinetika $x aplikace a dávkování $7 D009173
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a imunosupresiva $x farmakokinetika $x aplikace a dávkování $7 D007166
- 650 12
- $a transplantace orgánů $7 D016377
- 650 _2
- $a rejekce štěpu $x prevence a kontrola $7 D006084
- 650 _2
- $a individualizovaná medicína $7 D057285
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ryšánek, Pavel $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0239090
- 700 1_
- $a Hartinger, Jan $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0224709
- 700 1_
- $a Slanař, Ondřej $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0058262
- 700 1_
- $a Šíma, Martin $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. martin.sima@lf1.cuni.cz $7 xx0222901
- 773 0_
- $w MED00013414 $t Prague medical report $x 1214-6994 $g Roč. 125, č. 3 (2024), s. 187-194
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39171547 $y Pubmed
- 910 __
- $a ABA008 $b A 7 $c 1071 $y p $z 0
- 990 __
- $a 20241004 $b ABA008
- 991 __
- $a 20250513151734 $b ABA008
- 999 __
- $a ok $b bmc $g 2316503 $s 1229569
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 125 $c 3 $d 187-194 $e - $i 1214-6994 $m Prague medical report $n Prague Med Rep $x MED00013414
- GRA __
- $a VFN00064165 $p Ministerstvo Zdravotnictví Ceské Republiky
- LZP __
- $b NLK124 $a Pubmed-20241004
